Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies.
Stoyanova, Radka; Pollack, Alan; Takhar, Mandeep; Lynne, Charles; Parra, Nestor; Lam, Lucia L C; Alshalalfa, Mohammed; Buerki, Christine; Castillo, Rosa; Jorda, Merce; Ashab, Hussam Al-Deen; Kryvenko, Oleksandr N; Punnen, Sanoj; Parekh, Dipen J; Abramowitz, Matthew C; Gillies, Robert J; Davicioni, Elai; Erho, Nicholas; Ishkanian, Adrian.
; 7(33): 53362-53376, 2016 Aug 16.
Artigo em Inglês | MEDLINE | ID: mdl-27438142
Does an asymmetric lobe in digital rectal examination include any risk for prostate cancer? results of 1495 biopsies.
Evaluation of PCA3 and multiparametric MRI's: collective benefits before deciding initial prostate biopsy for patients with PSA level between 3-10ng/mL.
Predictive role of Trimprob associated with multiparametric MRI in the diagnosis of prostate cancer.
Prostate cancer volume estimations based on transrectal ultrasonography-guided biopsy in order to predict clinically significant prostate cancer.
Prostate-specific antigen testing in men between 40 and 70 years in Brazil: database from a check-up program.
Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?
Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy.
Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach?
Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer.